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Background: Female Genital Tuberculosis (FGTB) is one form of extra pulmonary tuberculosis affecting the female 
reproductive organs, most commonly the fallopian tubes and the endometrium. It affects young women aged between 
20 and 40 years of age and is an important cause of infertility. It often occurs as a secondary complication following 
pulmonary tuberculosis. Diagnosis depends mainly on clinical suspicion in countries where facilities for mycobacterial 
culture and histopathology are unavailable. Even in places where these facilities exist, diagnosis still remains difficult 
because of the lower sensitivity and specificity of the methods as well as the invasive procedure of acquiring biopsy 
specimens. 
Objective: To explore the immunological profiles of female genital tuberculosis (FGTB) patients in response to 
mycobacterial antigens. 
Methods: Twenty-five clinically suspected cases of FGTB and 12 control subjects who came to the Black Lion 
hospital for unrelated gynecological problems were included in the study. Peripheral blood samples were collected 
from each subject. Plasma was separated by centrifugation and PBMC were isolated over ficoll-hypaque and 
stimulated in vitro with mycobacterial antigens to examine their proliferative response as incorporation of tritiated 
thymidine using a β-counter. HIV status and total IgG-, IgA- and IgM- antibody levels were determined by ELISA 
tests. 
Results: In vitro recall responses to M. tuberculosis antigens (PPD and BCG sonicate) as well as plasma levels of IgG- 
IgA- and IgM-antibodies to MPT59 showed statistically significant differences between the patients and the controls 
(p< 0.05). 
Conclusion: The results show that PBMC of FGTB patients recognize M. tuberculosis antigens more strongly than 
PBMC of patients with other gynecological problems.  [Ethiop.J.Health Dev. 2005;19(3):219-224] 
 
Introduction 
Female genital tuberculosis (FGTB) is one type of extra 
pulmonary tuberculosis affecting the female genital 
organs. In 90% of cases the fallopian tubes are the 
primary foci of infection. From here the bacilli often 
disseminate to infect the ovaries (10-30%), endometrium 
(50%), cervix (<5%) as well as the vagina and vulva 
(<1%) (1,2). The most affected groups (80-90%) are 
women between 20 and 40 years of age (1,3).  
 
Prior to the onset of the HIV epidemic, extra pulmonary 
TB used to occur in relatively a few (about 15 %) FGTB 
cases (4). With the onset of the HIV epidemic, however, 
the occurrence has increased both in absolute and relative 
numbers with up to 62% extra pulmonary involvement in 
patients with advanced HIV status according to one study 
(5). Thus, HIV has emerged as a most important risk 
factor in the progression of new or dormant TB infection 
to clinical stages of the disease (6).  
 
The most frequent clinical symptoms of FGTB are: 
infertility, lower abdominal distention and pain, menstrual 
irregularity, fallopian tube abscess, ectopic pregnancy, 
weight loss, pelvic mass and signs of TB elsewhere in the 
body (3). 
 
Diagnosis of FGTB is usually made based on clinical 
suspicions (7), and in cases where the appropriate 
facilities are available, microbiological (AFB staining 
and culture), histopathological (8) and radiological 
methods (HSG) are deemed valuable (9,10). Also in 
cases where the required highly skilled personnel and 
specialized equipment are available, molecular methods 
such as the Polymerase Chain Reaction (PCR) might be 
employed to detect mycobacterial DNA using specific 
primers. The technique is rapid and sensitive (11). In 
lung tissue PCR for M. tuberculosis DNA is found to be 
frequently positive during latency (12), and thus it might 
be difficult to differentiate between latent infection and 
active disease by PCR.  All the above methods target the 
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organism attempting to directly demonstrate its presence 
in tissue or reveal morphologically characteristic lesions 
caused by the bacilli. 
 
An alternative approach is to exploit the specific nature 
of immune responses to invading pathogens by eliciting 
the recall response upon secondary exposure in vitro.  
The use of humoral or cellular responses to detect the 
presence of tuberculous infection or disease is an area 
under investigation (13).  By using PBMC obtained from 
FGTB suspected patients and controls, this study 
attempted to investigate immune responses to 
mycobacterial antigens (lymphocyte proliferation assay 
to BCG sonicate and Purified Protein Derivative, PPD, 
and antibody responses to MPT59, a secreted protein of 
M. tuberculosis) to assess whether these immunological 




Thirty-seven women, 25 of whom are suspected to have 
genital TB on clinical grounds (patients), and 12 controls 
were included in the study. Most patients came to the 
hospital and TB was suspected on clinical basis due to 
infertility problem, and laboratory findings. The controls 
were gynecological patients who underwent surgery due 
to other gynecological problems (mainly with cancer) 
having no clinical signs or symptoms suggestive of 
tuberculosis. Surgically excised tissue was taken from 
both groups for laboratory examination, including AFB 
using light microscopy following concentration and 
staining by ZN as well as culture and M. tuberculosis-
specific PCR (14). 
 
The study was approved by the Ethical Review 
Committees of AHRI/ALERT, the Department of 
Obstetrics and Gynecology (Medical Faculty of Addis 
Ababa University), and the National Ethical Review 
Committee (Ethiopian Science and Technology 
Commission).  Informed consent was obtained from all 
the women included in the study. 
 
Antigens: MPT59 (Antigen 85B, Rv1886c, is a major 
secreted protein in M. tuberculosis culture filtrates 
containing reactive B cell epitopes) (15, 16) and BCG 
sonicate were obtained as previously described (15). PPD 
was obtained from the Statens Serum Institute, 
Copenhagen, Denmark, and PHA was purchased from 





Isolation of PBMC 
Venous blood (10ml) was drawn in heparinized tubes, 
centrifuged, and the plasma separated. The pellet was 
diluted with RPMI-1640 in a one to one ratio and layered 
over Ficoll-Hypaque (Pharmacia, Uppsala, Sweden). It 
was then centrifuged for 30 minutes at 1800 rpm and at 
room temperature. Peripheral Blood Mononuclear Cells 
(PBMC) were collected and washed three times with 
RPMI-1640, each time centrifuged at 1500 rpm for five 
minutes at 4
0
C. PBMC were resuspended in two ml of 
5% Normal Human Serum (NHS) and stored in liquid 
nitrogen.  Plasma was stored frozen at –20
0
C until it was 
used. 
 
HIV antibody testing by ELISA 
The study subjects were tested for HIV antibodies using a 
microelisa system kit (Vironostika, HIV Uni-Form 11 
Plus, Organon Teknika GmbH, Eppelheim, The 
Netherlands in accordance with the manufacturer’s 
instructions. 
 
Lymphocyte Stimulation Test (LST) 
PBMC were cultured in 96 well tissue culture plates 
(Flow laboratory, Irvine KA1 28NB, Scotland) at a 
concentration of 10
5
 cells/well in the presence of PHA 
(1µg/well) or PPD (10 µg/ well (Statens Serum Institute, 
Copenhagen, Denmark) or BCG sonicate in 5% NHS 
supplemented with 5% glutamine and 5% Penicillin-
Streptomycin in RPMI as culture medium and incubated 
at 37
0
C in 5% CO2.  Then, the cells were pulsed with 
tritiated thymidine (Amersham, Little Chalfont, UK) 
(1µCi/well) at day three (PHA) and day six (BCG and 
PPD).  After 18 hrs, the cells were harvested on to a filter 
mat (cat. No. 11731).  Finally, proliferation was 
measured on a β-liquid scintillation counter (LKB Wallac 
1216 Rackbeta II, Uppsala, Sweden) and the stimulation 
index (SI) was calculated by dividing the CPM (counts 
per minute) of antigen stimulated cells with the CPM of 
non stimulated controls. 
 
ELISA (Enzyme Linked Immuno Sorbent Assay) 
Flat-bottomed 96 well plates (Immulon-2 Dynatech 
Laboratories, Chantilly, VA, USA) were coated with 0.5 
µg/ well of purified antigen, MPT59 in phosphate 
buffered saline (PBS) (pH 7.2) and incubated overnight 
at 4
0
C. The plates were then washed four times with 
0.1% Tween in PBS (PBS-T) and blocked with 100 µl of 
blocking buffer (5mg bovine serum albumin/ml in PBS) 
and incubated for 2 hrs at room temperature (RT). Serum 
samples were diluted 1:50 for IgG- and IgM- and 1:10 
for IgA antibody assay and added at 100 µl/well and 
incubated for 1 hr at RT. After washing four times in 
0.1% PBS-T, 100 µl of peroxidase conjugated secondary  
antibody (anti-human IgG/IgA/IgM) (Sigma) (1 mg/ml) 
diluted 1:10,000 was added and incubated for 1 hr at RT. 
Finally, 100 µl/well of the substrate o-Phenylenediamine 
Dihydrochloride (OPD) was added and incubated for 30 
minutes. The reaction was stopped by adding 50 µl stop 
solution (1M H2SO4) to each well. The optical density 
(OD) was read at 492 nm using an ELISA reader 
(Titertek Multiskan Plus, Helsinki, Finland). 
 
Statistical analysis 
Statistical analysis was carried out using the Mann-
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Whitney rank sum test. Fisher's exact test was also used 
to compare proportions. Differences among groups were 
considered to be significant when the p-value was found 
to be less than or equal to 0.05. 
 
Results 
Among the 37 study subjects, 25 were suspected 
clinically to have FGTB and out of these 25 suspected 
cases, 16 were confirmed to be positive for M. 
tuberculosis based on laboratory findings (14). The main 
clinical symptoms detected in the patient group were 
infertility. Out of the 17 patients whose infertility status 
was known, six (35%) had primary and 11 (65%) had 
secondary infertility. Other symptoms included lower 
abdominal pain, irregular menstrual bleeding and pelvic 
mass, (Table 1). The age range of the patients was 
between 18-39 years and the median age was 28. 
Immunological assays 
HIV status 
To determine the HIV status of the study subjects, HIV-
ELISA test was performed for 34 patients (22 patients 
and 12 controls). The result showed that 15 out of the 34 
(43%) patients were HIV positive. The proportion of 
seropositivity among patients was found to be 44% 
compared to 25% among the controls (p<0.05). 
 
Antibody Assay 
An antibody assay was performed using MPT59 as an 
antigen on the solid phase in the ELISA test. Fig. 1 
shows the plasma level of the three antibody isotypes 
irrespective of their HIV status. 
 
Table 1:  Clinical presentation and laboratory findings in 25 women who visited Tikur Anbessa Hospital for 
infertility problem and who are suspected to have genital tuberculosis 
Patient Signs and Symptoms AFB Culture Histology PCR 
M-003 2
0
 infertility, bilateral tubal blockage - - + - 
M-006 2
0












 infertility, bilateral tubal blockage, irregular menses, pelvic pain, 











 infertility + + + + 
M-017 1
0
 infertility, bilateral tubal blockage - - - + 
M-020 1
0
 infertility, vaginal discharge, adhesion, lower abdominal mass, 
pain 
- + - + 
M-024 2
0
 infertility, bilateral tubal blockage, amenorrhoea - + + + 
M-028 2
0
 infertility, bilateral tubal blockage - - - + 
M-032 2
0
 infertility. bilateral tubal blockage, lower abdominal pain - - - + 
M-037 Adhesion - - - + 
M-041 Pelvic pain - - - - 
M-045 1
0
 infertility, bilateral hydrosalpinx, ammenorrhoea - - - - 
M-049 2
0
 infertility, bilateral tubal blockage, vaginal discharge - - - + 
M-053 2
0
 infertility, bilateral tubal blockage - - + + 
M-057 1
0
 infertility - - - + 
M-060 1
0
 infertility - - - - 
M-063 2
0
 infertility, infertility, abdominal swelling - - - - 
M-066 Right tubal blockage, adhesion - - - + 
M-069 Irregular menses, vaginal bleeding, lower abdominal pain - - + - 
M-072 2
0
 infertility - - - - 
M-077 1
0
 infertility - - - - 
M-081 1
0
 infertility, bilateral tubal blockage - - - - 
M-086 1
0
 infertility, bilateral tubal blockage, vaginal discharge, adhesion - - + - 
M-089 1
0
 infertility, bilateral hydrosalpinx, dysmenorrhoea - - - + 
M-093 2
0
 infertility, tubo-peritionial factor - - - - 
 Total positive 1 3 7 12 
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Table 1 continued...... 
Patient Signs and Symptoms TB status HIV CD4/CD8 (ratio) 
M-003 2
0
 infertility, bilateral tubal blockage + - ND 
M-006 2
0










 infertility, bilateral tubal blockage, irregular menses, pelvic pain, 









 infertility + ND ND 
M-017 1
0
 infertility, bilateral tubal blockage + + ND 
M-020 1
0
 infertility, vaginal discharge, adhesion, lower abdominal mass, 
pain 
+ ND ND 
M-024 2
0
 infertility, bilateral tubal blockage, amenorrhoea + + ND 
M-028 2
0
 infertility, bilateral tubal blockage + - 27/33 (0.8) 
M-032 2
0
 infertility. bilateral tubal blockage, lower abdominal pain + + 37/14 (2.6) 
M-037 Adhesion + + 23/53 (0.4) 
M-041 Pelvic pain - + 51/18 (2.8) 
M-045 1
0
 infertility, bilateral hydrosalpinx, ammenorrhoea - - 36/38 (0.9) 
M-049 2
0
 infertility, bilateral tubal blockage, vaginal discharge + - ND 
M-053 2
0
 infertility, bilateral tubal blockage + - 42/42 (1) 
M-057 1
0
 infertility + - 41/33 (1.2) 
M-060 1
0
 infertility  + 20/51 (0.4) 
M-063 2
0
 infertility, infertility, abdominal swelling  - 21/30 (0.7) 
M-066 Right tubal blockage, adhesion + - 44/30 (1.5) 
M-069 Irregular menses, vaginal bleeding, lower abdominal pain + + 33/28 (1.2) 
M-072 2
0
 infertility - + ND 
M-077 1
0
 infertility - ND 10/20 (1) 
M-081 1
0
 infertility, bilateral tubal blockage - + 34/35 (1) 
M-086 1
0
 infertility, bilateral tubal blockage, vaginal discharge, adhesion + - 30/39 (0.8) 
M-089 1
0
 infertility, bilateral hydrosalpinx, dysmenorrhoea + - ND 
M-093 2
0
 infertility, tubo-peritionial factor - + ND 
 Total positive 16 10  




All the clinically suspected FGTB cases were found to be 
reactive (IgG, IgA, IgM) to this antigen with variably high 
levels of ODs.  The difference in median antibody levels 
between the two groups was significantly different for all 
the three immunoglobulins: IgG, IgA and IgM (p<0.05). 
The data were analyzed based on HIV status, and showed 
that there was no statistically significant difference between 
HIV positive and HIV negative individuals regarding the 
antibodies of the three isotypes (p= 0.6). 
 
Lymphocyte Stimulation Test (LST) 
PBMC were subjected to LST test using the mitogen 
phytohaemaglutinin (PHA) as a control for proper cell 
viability and the mycobacterial antigens BCG sonicate and 
PPD. Fig. 2 shows the proliferative response of patients and 
controls to these antigens irrespective of their HIV status. 
Although there was a variation in the degree of response to 
stimulation, all subjects responded well to PHA, mean SI = 
39 in patients and SI =31 in controls. This difference was 
not significant (p > 0.05). There was however, a statistically 
significant difference between the patient and the control 




Although the magnitude of the prevalence of FGTB in 
Ethiopia is not known, it will remain an important 
gynecological problem as long as pulmonary TB is rampant. 
PBMC from FGTB patients react to mycobacterial antigens 
more strongly than PBMC from the controls (patients with 
other gynecological problems, mainly cervical cancer). This 
shows that  although  FGTB is a localized  disease, there  are  
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Figure 1:  Levels of antibodies to MPT 59 antigen in the plasma of patients suspected to have female genital 
tuberculosis and the control gynecological patients, Addis Ababa, 2002 
OD=Optical Density 
 













Figure 2:  Proliferative response to stimulation with mycobacterial antigens of PBMC from patients suspected to 
have female genital tuberculosis and control gynecological patients, Addis Ababa, 2002. 
SI=stimulation Index             PBMC=Peripheral Blood Mononuclear cells 
 
circulating memory T and B cells in the peripheral blood, 
which could be targeted for immune based diagnostic 
methods. 
 
Plasma from all the 25 patients clinically suspected of 
suffering from FGTB contained antibodies to the     
mycobacterial antigen, MPT59.  Another study by Parikh 
et al. conducted in Indian women (17) has produced 
similar results. This study confirms that all of their 20 
clinically diagnosed FGTB patients had IgG-, IgM- or 
IgA antibodies to a different type of M. tuberculosis 
antigen denoted as A60. The 100 % reactivity was 
achieved when the three antibody isotypes were tested in 
each individual patient since a patient without IgG 
antibodies could have IgM- or IgA antibodies and vice 
versa. Antibody positivity does not, however, indicate 
which organ is affected by tuberculosis. 
 
A similar result was obtained concerning the proliferative 
response of PBMC from patients to PPD and BCG. The 
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SI of patients was significantly higher than that of the 
control group to both PPD (p = 0.02) and BCG (p = 
0.03). 
 
One limitation in the study is the relatively small sample 
size employed and the fact that most of the controls were 
cancer patients. This could not be avoided because it is 
only from such patients that a biopsy material could be 
obtained for investigation. It is also possible that the 
weaker immune response seen in the control group could 
be due to a possibly immunocompromised status in these 
individuals.  Another confounder could be the expected 
different levels of progression in the HIV- infected 
individuals in the two groups. This is probably not the 
case, as the difference in the CD4:CD8 ratios in the 
patients and the controls were found to be statistically 
significant. 
 
FGTB patients are often diagnosed lately because of the 
lack of early detection methods, difficulties with 
confirmatory tests, and the need for surgical intervention 
to obtain the appropriate specimens for diagnosis. Early 
detection is crucial for the proper management of FGTB. 
Since diagnosis on clinical grounds alone is unreliable, 
less invasive techniques than surgical interventions are 
needed.  Tests based on the immune response patterns of 
the subjects using PBMC would be helpful in this regard. 
The findings of this study also provide the baseline 
information that PBMC from FGTB patients recognize 
mycobacterial antigens more strongly than cells from 
patients with other   gynecological problems.  Further 
studies are required to test whether immune response 
assays could serve as additional diagnostic tests in 
situations where the confirmation of localized 
tuberculosis becomes difficult using more thoroughly 
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